Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in Working CapitalDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash Items
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MediWound (MDWD) Cash from Discontinued Operations: 2014-2025

Historic Cash from Discontinued Operations for MediWound (MDWD) over the last 7 years, with Jun 2025 value amounting to -$4.1 million.

  • MediWound's Cash from Discontinued Operations rose 10.81% to -$4.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$12.1 million, marking a year-over-year decrease of 18.28%. This contributed to the annual value of -$13.6 million for FY2024, which is 30.19% down from last year.
  • According to the latest figures from Q2 2025, MediWound's Cash from Discontinued Operations is -$4.1 million, which was up 10.81% from -$4.6 million recorded in Q2 2024.
  • MediWound's Cash from Discontinued Operations' 5-year high stood at $652,000 during Q2 2023, with a 5-year trough of -$4.6 million in Q2 2024.
  • Over the past 3 years, MediWound's median Cash from Discontinued Operations value was -$4.1 million (recorded in 2025), while the average stood at -$2.7 million.
  • Its Cash from Discontinued Operations has fluctuated over the past 5 years, first soared by 116.04% in 2023, then crashed by 806.75% in 2024.
  • Quarterly analysis of 5 years shows MediWound's Cash from Discontinued Operations stood at -$2.2 million in 2021, then tumbled by 312.69% to -$4.1 million in 2022, then soared by 116.04% to $652,000 in 2023, then slumped by 806.75% to -$4.6 million in 2024, then climbed by 10.81% to -$4.1 million in 2025.
  • Its Cash from Discontinued Operations stands at -$4.1 million for Q2 2025, versus -$4.6 million for Q2 2024 and $652,000 for Q2 2023.